Institutional members access full text with Ovid®

Share this article on:

Beyond apoptosis in lupus

Colonna, Lucrezia*; Lood, Christian*; Elkon, Keith B.

doi: 10.1097/BOR.0000000000000083
SYSTEMIC LUPUS ERYTHEMATOSUS AND SJÖGREN'S SYNDROME: Edited by Mariana J. Kaplan

Purpose of review Systemic lupus erythematosus (SLE) is characterized by autoantibodies directed against nuclear autoantigens normally concealed from immune recognition in healthy individuals. Here, we summarize recently identified mechanisms of abnormal cell death leading to exposure and aberrant processing of nucleoprotein self antigens, and discuss their role in the SLE pathogenesis.

Recent findings During the past few years, the unveiling of several new forms of cell death has expanded our understanding beyond the simple view of ‘apoptotic’ versus ‘necrotic’ cell death. SLE patients show abnormalities in cell death at several levels, including increased rates of apoptosis, necrosis, and autophagy, as well as reduced clearance of dying cells. These abnormalities lead to an increased autoantigen burden and antigen modifications, such as nucleic acid oxidation that increases the inflammatory properties of self antigens. Recent investigations have highlighted the role of opsonins in determining the immunogenic versus tolerogenic characteristics of self antigens.

Summary Dysregulation of different forms of programmed cell death contributes to increased exposure, availability, and immunogenic characteristics of intracellular self antigens, which all participate in development of lupus autoimmunity. As our understanding of abnormalities of cell death in SLE advances, potential therapeutic opportunities await human implementation.

Division of Rheumatology, University of Washington, Seattle, Washington, USA

*Lucrezia Colonna and Christian Lood contributed equally to the writing of this article.

Correspondence to Keith B. Elkon, Division of Rheumatology, University of Washington, Mailbox 358060, 750 Republican Street, Seattle, WA 98109, USA. Tel: +1 206 543 3414; e-mail: elkon@uw.edu

© 2014 Lippincott Williams & Wilkins, Inc.